{"id":"NCT03018028","sponsor":"Novo Nordisk A/S","briefTitle":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","officialTitle":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-01-10","primaryCompletion":"2018-01-09","completion":"2018-08-15","firstPosted":"2017-01-11","resultsPosted":"2019-12-30","lastUpdate":"2021-01-15"},"enrollment":243,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Semaglutide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Liraglutide","otherNames":[]}],"arms":[{"label":"Oral semaglutide 3 mg","type":"EXPERIMENTAL"},{"label":"Oral semaglutide 7 mg","type":"EXPERIMENTAL"},{"label":"Oral semaglutide 14 mg","type":"EXPERIMENTAL"},{"label":"Oral placebo","type":"PLACEBO_COMPARATOR"},{"label":"Liraglutide 0.9 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in Asia. The aim of this trial is to investigate the dose-response relationship of once-daily dosing of three dose levels (3, 7 and 14 mg) of oral semaglutide versus placebo as monotherapy on glycaemic control in Japanese subjects with type 2 diabetes mellitus","primaryOutcome":{"measure":"Change in HbA1c (Week 26)","timeFrame":"Week 0, week 26","effectByArm":[{"arm":"Oral Semaglutide 3 mg","deltaMin":-1.1,"sd":0.8},{"arm":"Oral Semaglutide 7 mg","deltaMin":-1.7,"sd":0.8},{"arm":"Oral Semaglutide 14 mg","deltaMin":-1.7,"sd":0.8},{"arm":"Liraglutide 0.9 mg","deltaMin":-1.4,"sd":1.1},{"arm":"Placebo","deltaMin":-0.2,"sd":0.7}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"0.0799"},{"comp":"OG001 vs OG003","p":"0.3942"},{"comp":"OG002 vs OG003","p":"0.0272"},{"comp":"OG000 vs OG004","p":"<0.0001"},{"comp":"OG001 vs OG004","p":"<0.0001"},{"comp":"OG002 vs OG004","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"0.1958"},{"comp":"OG001 vs OG003","p":"0.1868"},{"comp":"OG002 vs OG003","p":"0.0077"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":15},"locations":{"siteCount":16,"countries":["Japan"]},"refs":{"pmids":["32998732","32333875","32267058","31903692"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":49},"commonTop":["Nasopharyngitis","Constipation","Upper respiratory tract inflammation","Nausea","Back pain"]}}